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The trade-off hypothesis of virulence evolution rests on the assumption that infection-
induced mortality is a consequence of host exploitation by parasites. This hypothesis lies 
at the heart of many empirical and theoretical studies of virulence evolution, despite 
growing evidence that infection-induced mortality is very often a by-product of host 
immune responses. We extend the theoretical framework of the trade-off hypothesis to 
incorporate such immunopathology, and explore how this detrimental aspect of host 
defense mechanisms affects the evolution of pathogen exploitation and hence infection-
induced mortality. We argue that there are qualitatively different ways in which 
immunopathology can arise, and suggest ways in which empirical studies can tease apart 
these effects.  We show that immunopathology can cause infection-induced mortality to 
increase or decrease as a result of pathogen evolution, depending how it covaries with 
pathogen exploitation strategies, and with parasite killing by hosts.  Immunopathology is 
thus an important determinant of whether public and animal health programmes will 
drive evolution in a clinically beneficial or detrimental direction. Immunopathology 
complicates our understanding of disease evolution, but can nevertheless be readily 
accounted for within the framework of the trade-off hypothesis. 







The best-studied evolutionary explanation of why parasites harm their hosts is the 
virulence trade-off hypothesis (Anderson & May 1982; Ewald 1983; Frank 1996; Day 
2003; Mackinnon et al. in press). This pathogen-centered theory asserts that virulence is a 
consequence of host exploitation by parasites.  Pathogens which more aggressively 
exploit their hosts are assumed to produce more transmission forms per unit time and/or 
for longer before immune clearance.  However, excessively exploitative pathogens risk 
killing their hosts and hence truncating their own infectious periods. Death through over-
exploitation is thus the fitness cost said to be curbing excessively virulent pathogens.  
Yet, extensive biomedical data shows that a very substantial proportion of infection-
induced mortality is due not to transmission-enhancing exploitation of hosts by 
pathogens, but is instead due to host immune responses against infection.  For instance, 
among the infections of greatest concern to the World Health Organization are a set of 
immune-mediated diseases including tuberculosis, malaria, dengue fever, and Chagas 
disease which, collectively, kill over 3 million people per year, (Graham et al. 2005). 
Here we ask how pathogen exploitation schedules should evolve given the reality of 
immune-induced host death.   
 
Infectious agents can kill hosts via at least two conceptually distinct routes.  If 
uncontrolled, parasites can directly kill hosts through excessive tissue damage. In the case 
of microparasites such as viruses, bacteria and protozoa, hosts are simply overwhelmed 
by parasite numbers. This is a major reason why immunodeficient animals die.  This 
mechanism of host death is that most often considered in current theory on virulence 
evolution: higher pathogen densities are assumed to be a consequence of greater host 
exploitation which, in the absence of host death, results in enhanced transmission.  
However, mortality rates often exceed that attributable to parasites alone.  Immune 
effector mechanisms can cause serious damage to host tissue, and the damage can be 
lethal.  The most extreme example is septic shock: the life-threatening symptoms of 
shock (multi-organ failure & low blood volume) stem from innate immune responses to 




bacteria, rather than direct effects of the bacteria themselves (Munford 2006). Likewise, 
lethal cases of prevalent tropical diseases such as malaria are frequently due to excessive 
immune effector activity rather than parasite density per se (Clark et al. 2004).  Influenza 
induces much more immunological activity than is necessary to clear the virus, and it is 
this excess activity that does most of the damage to the lung (Hussell et al. 2001; Xu et al. 
2004).  Recent outbreaks of H5N1 Avian flu, and possibly also the 1918 influenza 
pandemic, killed people because of excessively exuberant inflammatory responses known 
as cytokine ‘storms’ triggered by high viral titres (de Jong et al. 2006; Kobasa et al. 
2007).   
 
From a biomedical perspective, the costs of defence due to excessive or 
misdirected immune effector mechanisms appear to be both large and ubiquitous. 
Experiments on laboratory animals have revealed that immune effectors such as 
antibodies, superoxides and collagen cause the death of mammalian hosts fighting a huge 
range of infections: from flaviviruses such as West Nile (King et al. 2007) or poxviruses 
such as smallpox (Stanford et al. 2007) through to metazoan parasites such as 
schistosomes (Hoffmann et al. 2002). Indeed, bacterial virulence seems to be mostly due 
to immune over response rather than direct tissue damage by replication of bacteria 
(Margolis & Levin in press).  In immunology and clinical biomedicine, such immune-
mediated disease is usually termed immunopathology.  We here use this relatively 
concise term to mean damage to host tissue that is caused by the host’s own immune 
effector mechanisms.  We concern ourselves only with infection-related 
immunopathology, ignoring immunopathologies such as rheumatoid arthritis, which 
apparently occur independently of infection.   
 
In the framework presented here we consider infection-induced mortality to 
comprise two elements: mortality that is a direct consequence of parasite exploitation, 
and the mortality caused by host immune responses (and any interaction between the 
two).  For simplicity, we refer to the second of these elements as immunopathology but 
we note that the equations below are agnostic about the mechanistic basis of host-induced 
mortality.  Thus, the mortality cost of defence we are discussing incorporates other costs 




not generally labeled as immunopathology in biomedical research, including those arising 
from resource reallocation and energetic constraints (Rolff & Siva-Jothy 2003). Our 
purpose is to determine how immunopathology alters the evolution of parasite encoded 
virulence factors, and how this evolution then affects the total infection-induced 
mortality. Some previous models of virulence evolution have included aspects of 
immunopathology (e.g., Alizon & van Baalen 2005), but none has provided a systematic 
study of how immunopathology affects virulence evolution. Here we use a simple model 
to do so, and to illustrate that there are different ways in which immunopathology can act, 
each with its own consequences for virulence evolution. 
 
 
2. Theoretical Development 
 
Our approach supposes that there is a single trait of evolutionary interest in the 
parasite species, referred to as ‘exploitation level’. We use ‘exploitation’ in a very 
general sense, but practically, high exploiter pathogens might be those that secrete more 
tissue-degrading toxins, or more efficiently bind to host tissue or evade host responses. In 
many instances ‘exploitation level’ might be quantified as within-host parasite density. 
Whatever the underlying mechanism, our key assumption about exploitation is that it is 
positively associated with transmission rate between hosts. The traditional trade-off 
hypothesis also posits that exploitation is positively associated with the mortality rate of 
the host (e.g., higher parasite density leads, directly, to higher host mortality). Otherwise, 
intermediate levels of exploitation are not expected to evolve. We will typically make this 
assumption here as well, but as will be seen, it is not always a requirement for 
intermediate levels of infection-induced mortality to evolve.  
 
Provided there is no coinfection or superinfection, we expect natural selection to 
maximize the parasite’s R0. For a standard SI epidemiological model (Anderson & May 
1982), R0  has the form 
 






µ + c + γε .
         (1) 
 
Here ε is the parasite exploitation strategy, β  is transmission rate, µ is background host 
mortality rate, c is the recovery rate of infection via protective (parasite killing) immune 
responses, and γ  is a constant that scales the effect of host exploitation on the infection-
induced mortality (Frank 1996). In virtually all previous models, γ ε is what is taken as 
the definition of parasite virulence (Day 2002). The clearance rate, c, is the instantaneous 
rate at which infected individuals leave the infected class, and this is expected to be 
positively associated with a host’s investment in an immunological response. For 
example, higher concentrations of antibodies are expected to be associated with a higher 
rates of clearance. We note that most measures of exploitation and immune investment 
(and thus, the parameters ε,β,c ) typically vary during the course of an infection, whereas 
expression (1) implicitly assumes that these are constant. In such cases, the 
epidemiological parameters in (1) should be interpreted as averages across infection age 
(Appendix 1). Finally, we suppose that transmission rate increases with exploitation with 
diminishing returns (mathematically, β '(ε) > 0, β ' '(ε) < 0 ). 
 
Given expression (1) for parasite fitness, we can calculate the selection gradient 









µ + c + γε
.        (2) 
 
Expression (2) contains two terms, representing current and future reproduction by the 
parasite. The term dβ /dε  represents the transmission benefit of increased exploitation, 
and γ  is the survival cost of increased exploitation (i.e., a unit increase in exploitation 
increases the mortality rate by a factor γ ). The latter term is weighted by β /(µ + c + γε), 
which we will refer to as the value of survival; it is the future reproduction that a parasite 
can expect if the current infection survives (conversely, it is the reproduction that is given 
up if the current infection does not survive). At the ESS exploitation level, these costs 




and benefits exactly balance, making expression (2) zero (Frank 1996). From (2) it can 
also be seen that, in the absence of a direct mortality cost of exploitation (i.e., if γ = 0), 
exploitation is expected to evolve upwards without bound (because dβ /dε > 0).  
 
With immunopathology, the mortality rate of the host is increased, which requires 
an additional term in the denominator of expression (1) for parasite fitness.  Furthermore, 
immunopathology will often depend on pathogen exploitation, sometimes positively and 
sometimes negatively.  High viral loads apparently trigger the cytokine storms that cause 
fatal H5N1 infections in humans (de Jong et al. 2006). Similarly, immunopathology will 
often be an unavoidable consequence of clearing pathogens (also referred to as friendly 
fire, collateral damage, or bystander effects).  For example, immune-mediated destruction 
of malaria-infected red blood cells can have a constant proportional side effect on 
uninfected red blood cells (Haydon et al. 2002). In such cases, better control of parasites 
will come at the cost of increased self harm. On the other hand, hyperpathogenic strains 
of Marek’s disease virus in poultry are massively immunosuppressive because they 
destroy lymphoid organs, substantially reducing the potential for immunopathology 
(Davison & Nair 2004).  It is also possible that immunopathology be independent of both 
clearance and exploitation.  Filariasis (elephantiasis) is an immune-mediated disease 
which is not associated with worm elimination or with worm fecundity (Behnke et al. 
1992; Sartono et al. 1997). Finally, it also easy to envisage that, in a statistical sense, 
immunopathology could be associated with an interaction between rates of exploitation 
and clearance. Thus our formulation allows immunopathology to depend on the parasite 
exploitation rate as well as host recovery rate in arbitrary ways. 
 
We define the function, f (ε,c)  to be the additional mortality due to 
immunopathology, and α(ε,c) ≡ γε + f (ε,c) to be the total infection-induced mortality, 
including both exploitation and immunopathology. This separation of sources of 
mortality into those directly related to host exploitation and those related to 
immunopathology is conceptually useful, but in practice it will typically not be possible 
to separate these two so clearly. This is of no consequence to the results below, however, 
since all analyses can be conducted on the total infection-induced mortality.  





With these specifications, expression (1) then becomes 
 
˜ R 0(ε,c) =
β(ε)
µ + c + α(ε,c)
.        (3) 
 
We can again calculate the selection gradient on exploitation by differentiating (3) with 
respect to ε, giving; 
 















µ + c + γε + f (ε,c)
.      (4) 
 
A comparison of expression (2) with expression (4) reveals that immunopathology has 
two effects on parasite evolution. First, it always decreases the value of survival because 
any infection that survives will no longer be as productive in the future (owing to the 
additional mortality; the f term in the denominator of (4)). This selects for increased 
exploitation. Second, if the extent of mortality caused by immunopathology depends on 
the level of parasite exploitation (i.e., ∂f /∂ε ≠ 0), then the survival cost of exploitation 
will also change. For example, if mortality due to immunopathology increases with 
exploitation level, then the survival cost of exploitation will increase. The reason is 
simply that differences between strains in exploitation will then translate into larger 
differences in the probability that an infection will survive (i.e., γ  in the absence of 
immunopathology versus γ + ∂f /∂ε  in the presence of immunopathology). This then 
selects for decreased exploitation. These considerations yield the following conclusions: 
if the extent of immunopathology is independent of exploitation, or if it decreases with 
increasing exploitation, then immunopathology always causes the ESS level of 
exploitation to increase. If the extent of immunopathology is positively associated with 
the level of exploitation, however, then immunopathology causes a smaller increase in 
the ESS exploitation level, and can even cause it to decrease (Figure 1). 
 




The above conclusions are phrased in terms of the ESS exploitation level, but the 
total infection-induced mortality rate is typically of more interest (and is more readily 
observable). This latter quantity is the summed effect of the exploitation level of the 
parasite, γε , as well as the mortality due to immunopathology itself, f (i.e., 
α(ε,c) = γε + f (ε,c)). Again, if immunopathology affects mortality rate independently of 
the level of parasite exploitation, or if it decreases with increasing exploitation, then 
immunopathology always causes the infection-induced mortality at the ESS level of 
exploitation, α(ε*,c), to be larger than when immunopathology is absent. The reason is 
simply that the ESS level of exploitation will be larger in this case, and the existence of 
immunopathology itself (i.e., f) increases the mortality rate, α . If the mortality due to 
immunopathology increases with increasing exploitation, however, then the mortality 
directly due to exploitation, γε , will be affected less and might even decrease. At the 
same time, however, the existence of immunopathology itself will increase mortality. 
Therefore the sum, γε + f (ε,c), might be larger, smaller, or remain unchanged. 
Furthermore, since case mortality is monotonically related to α , the same qualitative 
conclusions hold if we quantify infection-induced mortality as the probability of an 
infection ending in death (conventionally called the case fatality rate in the biomedical 
literature; Day 2002). 
 
To gain a more concrete appreciation for the above general results, it is helpful to 
specify a functional form for f (ε,c) . A precise relationship between immunopathology 
and the rates of exploitation and clearance can sometimes be derived from assumptions 
about the mechanistic details of within-host parasite replication and the immune response 
(e.g., Krakauer & Nowak 1999; Wodarz & Krakauer 2000). The information required to 
do so is often not available, however, and therefore we take a more phenomenological 
approach.  
 
Consider an experiment aimed at quantifying how infection-induced mortality 
changes in response to changes in clearance rates and/or exploitation (the latter perhaps 
being most readily measured as parasite density). The data might be analyzed using a 
two-way ANOVA, with exploitation and clearance as predictor variables. The linear 




statistical model behind the analysis would have a constant term, a term for the main 
effects of each variable, and a term for their interaction. Thus, the simplest complete 
expression for the mortality arising from immunopathology is 
 
f (ε,c) = φ0 + φ1ε + φ2c + φ3εc .        (5) 
 
With this choice of f, the parameter φ0  specifies the degree of immunopathology that is 
independent of both recovery and exploitation, φ1 and φ2  determine its dependence on 
exploitation and recovery rate respectively, and φ3  determines the extent to which an 
interaction between exploitation and recovery affect immunopathology.  
 
To take this example further, suppose that β(ε) = εn , where 0 < n < 1 is a 
parameter affecting the transmission benefits of increasing exploitation (n < 1 implies 





µ + φ0 + c(1+ φ2)
γ + φ1 + cφ3
.        (6) 
 
The effect of immunopathology on the ESS level of exploitation can be seen by 
comparing the full expression (6) to the case where we set the φ i in (6) to zero. For 
example, if φ1 = φ3 = 0, then immunopathology is independent of the level of 
exploitation. In this case, equation (6) illustrates the general prediction that such 
immunopathology causes the ESS level of exploitation to be larger (Figure 2a). On the 
other hand, if immunopathology increases with exploitation, then the ESS exploitation 
can be smaller than that occurring in the absence of immunopathology. In particular, the 









The total infection-induced mortality at the ESS is also readily calculated for this 
model (provided that ε * is finite): 








(µ + c) +
φ0 + cφ2
1− n
.       (7) 
 
Equation (7) can be compared to the classical result, α(ε*,c) = n(µ + c) /(1− n)
 
in which 
there is no immunopathology. In this case we can see that the infection-induced mortality 
at the ESS level of exploitation is always larger than the classical result provided that 
there is some immunopathology that is independent of exploitation (i.e., if φ0 > 0 and/or 
if φ2 > 0). (Figure 2a). On the other hand, if all immunopathology is positively associated 
with exploitation (φ0 = φ2 = 0 but 0or and/ 0 31 >> φφ ) then, in this example, the 
mortality rate at the ESS is identical to that which occurs in the absence of 
immunopathology. This second prediction is somewhat counter-intuitive and occurs 
because of the contrasting effects that immunopathology has on infection-induced 
mortality. If immunopathology acts solely in response to exploitation, then the ESS level 
of exploitation will be smaller (as seen in eqn 6). At the same time the additional 
mortality caused by the immunopathology itself counteracts this effect. In this specific 
example, these two opposing factors happen to exactly cancel; the total infection-induced 
mortality remains unchanged, but the part of this that is directly due to exploitation is 
decreased (at evolutionary equilibrium) and this decrease is exactly compensated for by 
the extra mortality arising from immunopathology (Figure 2b).  In other cases, the two 
opposing forces need not exactly cancel, so that infection-induced mortality at the new 
pathogen ESS can be smaller or larger than it would be in the absence of 
immunopathology. 
 
Equation (6) also clearly illustrates that, in the presence of immunopathology, 
intermediate levels of exploitation can evolve even if exploitation does not directly cause 
host mortality (i.e., if γ = 0). There is evidence that the mortality experienced by mice 
infected with Lymphocytic Choriomeningitis Virus (LCMV) is entirely due to host 
defense mechanisms. LCMV is a non-cytopathic virus and thus, in the absence of a 
strong, antigen-specific immune response, the virus can persist in mice without causing 
detrimental effects (Moskophidis et al. 1995; Moskophidis & Zinkernagel 1996). The 




occurrence of a CD8+ T cell response can clear the virus by lysing infected cells, but this 
tends also to be detrimental to the host because of collateral damage to the meninges. In 
the context of equation (6) this might be described by setting γ = φ0 = φ1 = 0. Thus, so 
long as the mouse population is immunocompetent, exploitation and thus transmission 
(and infection-induced mortality) will evolve to intermediate values. For a population of 
immunodeficient hosts, however, exploitation and thus transmission would evolve to very 
high values. 
 
 Finally, it is useful to consider how the presence of immunopathology alters the 
effect of host-mediated parasite killing on parasite evolution. Previous analyses of the 
evolution of virulence in the absence of immunopathology have demonstrated that ESS 
exploitation and thus virulence increases as host recovery rate increases (van Baalen 
1998; Day & Burns 2003). A comparison of expressions (2) and (4), however, reveal that 
immunopathology has the potential to qualitatively alter this prediction. An increase in 
recovery rate reduces the value of survival by decreasing future reproductive output. This 
selects for increased exploitation. At the same time, if the dependence of 
immunopathology on exploitation is affected by recovery (i.e., an c* interaction, where  
∂f /∂ε  in expression 4 increases with recovery rate) then the survival cost of increased 
exploitation is also increased. This generates selection for decreased exploitation. The net 




Several authors have pointed out that the fact that host responses cause much 
disease is a complication for parasite-centric trade-off models of virulence evolution (e.g.  
Lipsitch & Moxon 1997; Ebert & Bull 2003; Graham et al. 2005; Ebert & Bull in press; 
Margolis and Levin in press).  Here we have shown formally that this is indeed so, but 
that the trade-off framework can be expanded to accommodate this reality.   
 
Immunopathology has two broad classes of effect on infection-induced mortality 
when parasites are allowed to evolve.  First, if the degree of mortality induced by 




immunopathology is independent of the level of exploitation by the parasite, then there 
will be higher host mortality at the ESS than there would be in the absence of immune-
mediated disease.  Second, if immunopathology increases with parasite exploitation, then 
immunopathology will have a smaller effect on the infection-induced mortality rates at 
the ESS, and might even lead to pathogen evolution which lowers overall infection-
induced mortality.  
 
From this, we make several predictions.  All else equal, we expect the highest 
infection-induced mortality in host-pathogen systems where there is a lot of 
immunopathology which is relatively independent of the exploitation. This is because 
immune self harm undermines the survival benefits of restrained exploitation and this sort 
of immunopathology will occur whatever the parasite does.  In contrast, overall mortality 
rates should be lower in systems in which immune-mediated disease rises as parasite 
exploitation increases.  Here, evolution will favour pathogen strains better able to avoid 
inducing immunopathology.   
 
The same logic also generates related predictions about the relative contributions 
of direct pathogen damage and immunopathology to disease outcome. A large component 
of infection-induced mortality will be due to direct damage by the pathogen in systems 
where immunopathology is strong and is relatively independent of what the pathogen 
does.  Again this is because, all else equal, exploitation-induced mortality is expected to 
increase in the presence of such immunopathology (Figure 2a).  In contrast, in systems 
where immunopathology is a consequence of pathogen exploitation, the contribution to 
overall mortality of direct pathogen damage will be lower relative to that due to immune 
self harm.  Selection will favour less exploitative pathogens where exploitation-related 
mortality is further inflated by exploitation-related immunopathology (Figure 2b). 
 
Modern laboratory immunology provides a toolkit to experimentally disentangle 
parasite- and immunologically-derived mortality, especially in rodent models of 
infectious disease.  For example, reagents are commercially available that can enhance 
immune responses against microparasites such as malaria (Li et al. 2003). In effect, these 




reagents remove regulatory control of immune effector mechanisms.  In the case of 
malaria, use of such reagents increased the proportion of malaria virulence that, prior to 
parasite clearance, is due to immunopathology rather than parasite density (Long et al., 
unpublished ms).  In terms of equation (5), this might represent a manipulation of 
clearance rate, and thus would indicate that φ2 > 0 and/or φ3 > 0 for this pathogen (i.e., 
higher clearance rates result in greater disease severity). An opposing treatment (also 
commercially available) that depletes immune effectors but has no effect on parasite 
densities reduced malaria virulence, further indicating that φ2 > 0 and/or φ3 > 0 in this 
system (Long et al. 2006). One could therefore use such treatments to determine if 
parasite exploitation evolves in a way predicted by the theory. Experimental evolution in 
such systems would be difficult but, by analogy with other studies  (e.g. Mackinnon & 
Read 2003), it should be possible to compare the fitness of high and low virulence 
parasite strains, and deduce which would be favoured by selection in different immune 
environments. 
 
Various clinical and public health interventions can also affect infection-related 
immunopathology.  How would we expect infected-induced mortality to evolve in 
response to these?   Previous studies have focused on the evolutionary consequences of 
vaccination, and have shown that predictions about pathogen evolution depend on 
whether vaccination affects transmission rate, parasite induced mortality, or clearance 
rate (Gandon et al. 2001; Mackinnon et al. in press). In the presence of 
immunopathology, vaccines can have even more varied and subtle effects that will 
influence pathogen evolution and hence infection-induced mortality. With malaria, for 
example, much pathogenesis is due to a proinflammatory cytokine cascade triggered by 
parasite molecules such as glycosylphosphatidylinositol  (GPI).  These responses are 
believed to be first line defenses necessary to control otherwise lethal pathogen 
replication during acute primary infections.  However, the responses themselves cause 
substantial collateral damage to the host (Clark et al 2004). Antibody-mediated control of 
parasites takes longer to develop but is associated with considerably less immune-
mediated disease.  Many candidate malaria vaccines are aimed at priming protective 
antibody response, which should achieve parasite control without proinflammatory 




immunopathology.  Moreover, some candidate vaccines are aimed at directly reducing 
immune-mediated disease by eliciting anti-GPI antibodies to deliberately remove these 
potent immunostimulatory parasite molecules (Schofield & Grau 2005; Riley et al. 2006).  
What will be the consequences of these sort of vaccines on pathogen evolution? 
 
Space limitations preclude a full analysis of the evolutionary consequences of 
different kinds of vaccines here, but a few predictions can be made using the results 
already obtained. In the absence of immunopathology, vaccines that increase clearance 
rate are predicted to lead to the evolution of higher levels of exploitation (Gandon et al. 
2001). With immunopathology, however, the outcome will depend on the extent to which 
there is an interaction between recovery rate and exploitation in determining 
immunopathology. If the effect of exploitation on immunopathology is independent of 
the rate of parasite clearance, then earlier predictions remain valid (Gandon et al. 2001). 
In the presence of a positive interaction between exploitation and recovery the predicted 
effect can be reversed (clearance-enhancing vaccines lead to the evolution of lower 
exploitation).  
 
Another possibility is that a vaccine simply reduces the degree of 
immunopathology experienced by the host. The proposed anti-GPI malaria vaccines 
discussed above are intended to act in this way (Schofield & Grau 2005; Riley et al. 
2006). If immunopathology is independent of exploitation, then reducing immune-
mediated disease via vaccination will lead to an evolutionary reduction in exploitation 
and thus infection-induced mortality (as measured in an unvaccinated host).  This is 
because the vaccines are, in effect, reducing mortality over which the parasite has no 
control, increasing the fitness gains to be had by exploiting the host more prudently. If 
immunopathology increases strongly with exploitation, then a reduction in 
immunopathology via vaccination will lead to an evolutionary increase in exploitation 
and thus higher mortality rates among the unvaccinated.  Anti-GPI vaccines will probably 
do this because concentrations of GPI molecules, which come from parasite membranes, 
almost certainly increase with parasite density and replication rate.  If so, the widespread 
use of anti-GPI vaccines will allow more exploitative pathogen strains to spread because 




these strains can accrue the fitness benefits of exploitation at reduced cost (Gandon et al. 
2001; Mackinnon et al. in press).  More generally, however, vaccination might affect the 
various components of infection-induced mortality differently. For example, one can 
readily imagine vaccines whose effects arise from a modulation of the values of 
γ,φ0,φ1,φ2 , and φ3  in different ways. The evolutionary consequences of these vaccines 
would require a more in-depth analysis than is possible here. 
 
Other medical interventions which modulate immunopathology might also have 
similar effects on pathogen evolution, were their use to become sufficiently widespread.  
Statins, for instance, beneficially modulate the inflammatory cascades which trigger 
severe sepsis and shock, and their administration has been suggested as a potential 
prevention and treatment strategy (Terblanche et al. 2006; other analogous possibilities 
are reviewed by Margolis and Levin in press).  The efficacy of such measures in terms of 
symptom alleviation is relatively straightforward to determine through standard 
biomedical protocols.  The longer-term consequences of their use for pathogen evolution 
will require an interplay between experimental dissections of the sort discussed above, 
and models of the sort we have presented here.  By analogy with the vaccine discussion 
above, they could favour the evolution of more or less pathogenic parasites, depending on 
the details. 
 
The framework we have developed here could be extended in several directions.  
First, although the general results presented in equations (3) and (4) allow for any 
dependence of immunopathology on clearance and exploitation, most of our 
considerations have assumed that immunopathology either increases or decreases 
monotonically with these parameters. Theoretical studies of within-host pathogen 
replication and host immune responses suggest that the highest levels of 
immunopathology might sometimes occur at intermediate values of these parameters 
(Krakauer & Nowak 1999). In such cases is seems plausible that a greater variety of 
evolutionary outcomes would be possible.  
 




Second, we have supposed here that the sole impact of immunopathology on 
pathogen fitness is through increased host mortality.  In many cases, immunopathology 
also impacts on pathogen transmission while the host is alive.  For instance, disease-
causing cytokines elicited by malaria parasites transiently reduce infectiousness to 
mosquitoes (Karunaweera et al. 1992).  Immunopathology can also enhance transmission.  
In tuberculosis, for instance, immunopathological necrosis of the lung enhances 
transmission, and damage of host tissue by immune effectors is also associated with 
increased transmission in schistosomiasis, dengue and leishmaniasis (reviewed by 
(Graham et al. 2005).  Similarly, immunopathology causes considerable morbidity, and 
Ewald (1994) has argued that morbidity enhances transmission of many vector-borne 
diseases by reducing anti-vector behaviour in the host.  The evolution of exploitation 
strategies when immunopathology directly affects transmission rate () could be analysed 
using the framework adopted here, as could the situation where host death is required for 
transmission. 
 
Third, we have focused attention on the evolution of a single pathogen trait 
(exploitation level) but there are many other aspects of a pathogen’s life cycle that might 
evolve jointly with this trait. For example, the extent to which immunopathology occurs 
(as quantified by the φ  parameters in our model) is likely determined, in part, by the 
tissue in which the pathogen replicates. Replication in some tissues might elicit higher 
levels of immunopathology than others, if it is more difficult (e.g., in terms of killing 
efficiency per antibody) for the host to mount a pathogen-specific attack in those tissues. 
Thus the tissue tropism of a pathogen might evolve as a means to hide from host defense 
mechanisms. However, the extent to which this occurs will depend on the associated 
costs of such changes, including any reduced transmission potential that results, as well 
as any increased likelihood of eliciting immunopathology (which can be detrimental to 
both the host and parasite) in tissues that are acutely sensitive to inflammatory damage.  
These are issues that warrant a more detailed theoretical examination than is possible in 
the context of the current paper.  
 




Finally, it seems likely that in many cases, the degree of infection-induced 
mortality, as well as immunopathology, will often be the outcome of a coevolutionary 
dynamic between hosts and parasites (van Baalen 1998; Day & Burns 2003).  We have 
here considered only the evolution of the parasite, in part to be comparable with previous 
models of parasite virulence evolution, but also because for fast evolving pathogens, the 
evolution of hosts (particularly large vertebrates) can be safely ignored. However, a 
variety of coevolutionary scenarios can be envisaged, including the evolution of 
immunmodulatory manipulations by the pathogen, which might sometimes be mutually 
beneficial for both parasite and host.  Host evolution is also likely, with the optimal 
clearance rate dependent on how immunopathology scales with protective defense and 
what the pathogen is doing.  An analysis of the impact of immunopathology on the 





We thank three anonymous reviewers for comments that improved the presentation of 
these ideas. This work was begun when TD was on sabbatical in Edinburgh supported by 
a BBSRC International Fellowship, and finished when AR and AG were at the 
Wissenshaftskolleg zu Berlin.  Our empirical work is funded by the Wellcome Trust and 








APPENDIX 1 – When parameters depend on infection age. 
 




= θ − µS − βSI + cI
dI
dt
= βSI − µ + c + γε( )I,
       (A1) 
 
where S and I are the number of susceptible and infected hosts. Model (A1) implicitly 
assumes that clearance rate and exploitation (and thus transmission, β , and exploitation-
induced mortality, γε ) are constant during an infection. A simple extension of (A1) that 




= θ − µS − S β(a)I(a,t)da
0
∞









− µ + c(a) + γε(a)( )I(a, t)
    (A2) 
 
with boundary condition I(0,t) = S β(a)I(a, t)da
0
∞
 . Now, let’s define IT = I(a, t)da0
∞
  as 
the total number of infected individuals at time t. Also, for any function of infection age, 
x(a) , let’s define its average at time t as x ≡ x(a)I(a,t)
0
∞
 / IT . We can then integrate 




= θ − µS − β SIT + c IT
dIT
dt
= β SIT − µ + c + γε ( )IT .
       (A3) 
 
Over time we expect the age distribution of infections, I(a,t) / IT , to reach a steady state, 
making β ,ε ,c  constant. Thus, model (A3) can be seen as analogous to model (A1), 












Figure 1. Schematic of parasite fitness as a function of exploitation for three different 
scenarios: Solid – no immunopathology (ε * gives optimal exploitation); Short-dash – 
extent of immunopathology increases with increasing exploitation (ε1 gives optimal 
exploitation); Long-dash – immunopathology is independent of exploitation (ε2  gives 
optimal exploitation). Either form of immunopathology results in an overall reduction in 
pathogen fitness, but the optimal value of exploitation can be shifted up or down 
depending on how immunopathology acts. 
 
Figure 2. Infection-induced mortality (IMM) at the pathogen ESS exploitation, α(ε*,c), 
plotted against increasing strength of immunopathology (measured as φ0  in (a) and φ1 in 
(b)). Results based on equations (6) and (7). (a) All immunopathology is independent of 
exploitation. The infection-induced mortality at the pathogen ESS increases (solid black 
line), and the amount of this mortality due to immunopathology at the ESS increases 
(dark grey), as does that due to exploitation (light grey). Parameter values: n = ½, 
µ =1/(80 * 365), 10/3 ,2/1,0321 ===== cγφφφ . (b) All immunopathology is 
positively associated with exploitation. The infection-induced mortality at the pathogen 
ESS remains constant at 0.3 (solid black line), but the amount of this mortality due to 
immunopathology increases (dark grey), while that due to exploitation decreases (light 
grey). Parameter values: n = ½, µ =1/(80* 365), 10/3 ,2/1,0320 ===== cγφφφ . 
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